A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.’s copy of
The generic-drug maker is appealing rulings that block the early launch of its copy of the blockbuster heart-disease drug and preserve Novartis’ market exclusivity until a patent’s pediatric exclusivity expires in July. The US Court of Appeals for the Federal Circuit on May 2 ordered the district court to keep its temporary stay in effect as the appellate judges ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.